According to the company’s release, “The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape.
The combination of mutations represents a significant potential risk to accelerate the decline in natural and vaccine-induced immunity. A booster dose of a licensed vaccine represents the only currently available strategy to boost waning immunity. The Modern COVID-19 vaccine (mRNA-1273) is licensed as a booster for many populations at the 50 µg dose level. The company is working quickly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks. “
“From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we be proactive as the virus evolves. The mutations in the Omicron variant are worrisome and for several days we have moved as quickly as possible to execute our strategy to address this variant, ”said Stéphane Bancel, CEO of Moderna on Friday.
“We have three lines of defense that we are advancing in parallel: we have already evaluated a higher dose boost of mRNA-1273 (100 µg), second, we are already studying two multivalent boost candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant and data is expected in the next few weeks, and thirdly, we are making rapid progress on a specific Omicron booster candidate (mRNA-1273,529), “said the manager.
Source From: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
